Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 2/20 | 0.57 |
| ▸ | FTO | Q9C0B1 | 7/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL691296 | 0.92 | PTK2 (0.56) | PTK2FTOGAAMAPTGFER | |
| SCHEMBL691087 | 0.90 | PTK2 (0.60) | PTK2GAAMAPK3MAPK1JAK2 | |
| SCHEMBL691756 | 0.90 | PTK2 (0.59) | PTK2FTOGAAMT-CO2HPGD | |
| SCHEMBL690650 | 0.89 | PTK2 (0.54) | PTK2FTOGAAHPGDMAPK3 | |
| SCHEMBL690300 | 0.88 | PTK2 (0.75) | PTK2GAAPTGS2MAPK3MAPK1 | |
| SCHEMBL691625 | 0.87 | PTK2 (0.64) | PTK2GAAHPGDPTGS2MAPK3 | |
| SCHEMBL697233 | 0.87 | PTK2 (0.60) | PTK2FTOMAPTGFERMEN1 | |
| SCHEMBL691295 | 0.84 | PTK2 (0.78) | PTK2FTOMAPTGFERMEN1 | |
| SCHEMBL5465583 | 0.84 | GAA (0.62) | FTOGAAMAPTGFERMEN1 | |
| SCHEMBL691234 | 0.83 | MAPK3 (0.52) | PTK2MAPK3MAPK1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446034-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446034-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446034-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2016-04-07 | — | — | US | disclosed |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2016-04-07 | — | — | US | disclosed |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2016-04-07 | — | — | US | disclosed |
| US-20150265589-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2015-09-24 | — | — | US | disclosed |
| US-20150265589-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2015-09-24 | — | — | US | disclosed |
| US-20150265589-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2015-09-24 | — | — | US | disclosed |
| US-9012479-B2 | Pyrazolylaminopyridines as inhibitors of FAK | GLAXOSMITHKLINE LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-11-03 | — | — | US | disclosed |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-11-03 | — | — | US | disclosed |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-11-03 | — | — | US | disclosed |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-08-25 | — | — | US | disclosed |
| WO-2010062578-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885FTO 4746/4885GAA 4464/4885 |
| US-20160095841-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885FTO 4746/4885GAA 4464/4885 |
| US-20150265589-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885FTO 4746/4885GAA 4464/4885 |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885FTO 4746/4885GAA 4464/4885 |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885FTO 4746/4885GAA 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.